NASDAQ:MRSN - Mersana Therapeutics Stock Price, News, & Analysis

Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."

Mersana Therapeutics Inc (NASDAQ:MRSN) issued its earnings results on Wednesday, August, 15th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.58) by $0.04. The company had revenue of $4.19 million for the quarter, compared to analysts' expectations of $3.74 million. Mersana Therapeutics had a negative net margin of 440.47% and a negative return on equity of 110.44%. View Mersana Therapeutics' Earnings History.

Mersana Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March 27th 2019. View Earnings Estimates for Mersana Therapeutics.

6 Wall Street analysts have issued 1-year price targets for Mersana Therapeutics' shares. Their predictions range from $14.00 to $61.00. On average, they anticipate Mersana Therapeutics' share price to reach $26.80 in the next twelve months. This suggests a possible upside of 267.1% from the stock's current price. View Analyst Price Targets for Mersana Therapeutics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mersana Therapeutics.

Media coverage about MRSN stock has trended somewhat positive recently, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Mersana Therapeutics earned a news impact score of 1.3 on InfoTrie's scale. They also gave headlines about the company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Mersana Therapeutics saw a decrease in short interest in the month of January. As of January 31st, there was short interest totalling 589,489 shares, a decrease of 48.1% from the January 15th total of 1,136,169 shares. Based on an average trading volume of 138,454 shares, the days-to-cover ratio is presently 4.3 days. Approximately 5.6% of the shares of the stock are short sold. View Mersana Therapeutics' Current Options Chain.

Some companies that are related to Mersana Therapeutics include Dynavax Technologies (DVAX), Rocket Pharmaceuticals (RCKT), Revance Therapeutics (RVNC), Ra Pharmaceuticals (RARX), Arvinas (ARVN), Viking Therapeutics (VKTX), CymaBay Therapeutics (CBAY), Basilea Pharmaceutica (BPMUF), Synthorx (THOR), Kura Oncology (KURA), Lexicon Pharmaceuticals (LXRX), Urogen Pharma (URGN), ChemoCentryx (CCXI), Eidos Therapeutics (EIDX) and Crinetics Pharmaceuticals (CRNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Mersana Therapeutics investors own include Eyepoint Pharmaceuticals (EYPT), Progenics Pharmaceuticals (PGNX), Clearside Biomedical (CLSD), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), Dynavax Technologies (DVAX), Bausch Health Companies (BHC), Trevena (TRVN), Melinta Therapeutics (MLNT) and Array Biopharma (ARRY).

(MRSN) raised $75 million in an initial public offering (IPO) on Wednesday, June 28th 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Mersana Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.37%), Northern Trust Corp (0.60%), Geode Capital Management LLC (0.55%), Hikari Power Ltd (0.37%), Two Sigma Investments LP (0.29%) and Millennium Management LLC (0.19%). Company insiders that own Mersana Therapeutics stock include M James Barrett and Timothy B Lowinger. View Institutional Ownership Trends for Mersana Therapeutics.

MRSN stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, BlackRock Inc. and Northern Trust Corp. View Insider Buying and Selling for Mersana Therapeutics.

MRSN stock was acquired by a variety of institutional investors in the last quarter, including Hikari Power Ltd, Two Sigma Investments LP, Bank of America Corp DE, Bank of New York Mellon Corp, Geode Capital Management LLC and Rhumbline Advisers. View Insider Buying and Selling for Mersana Therapeutics.

Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MRSN stock can currently be purchased for approximately $7.30.

Mersana Therapeutics has a market capitalization of $169.21 million and generates $17.55 million in revenue each year. The company earns $-38,700,000.00 in net income (profit) each year or ($3.22) on an earnings per share basis. Mersana Therapeutics employs 78 workers across the globe.

The official website for Mersana Therapeutics is http://www.mersana.com.

Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-498-0020 or via email at [email protected]